Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Editas Medicine (EDIT)

$3.65 +0.37 (11.28%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	357.36M
Revenue (ttm)	40.52M
Net Income (ttm)	-160.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-395.01%
Debt to Equity Ratio	0.00

Volume	4,202,000
Avg Vol	2,559,686
Day's Range	N/A - N/A
Shares Out	97.91M
Stochastic %K	97%
Beta	2.10
Analysts	Sell
Price Target	$5.67

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalasse...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

KYC2018 Jul. 3 at 11:42 PM

$EDIT I believe you are right

0 · Reply

topstockalerts Jul. 3 at 9:45 PM

$EDIT this could catch a few people sleeping

0 · Reply

MarketMaestro1 Jul. 2 at 7:53 PM

This might be the fastest way to accumulate $1 million by the end of 2026: $DNA (Ginkgo Bioworks) → $8 Must buy $IONQ (IonQ) → $46 Must buy $EDIT (Editas Medicine) → $3.56 Must buy $FATE (Fate Therapeutics) → $3 Must buy $ADPT (Adaptive Biotechnologies) → $18 Must buy Next alert dropping soon! If you are not following us with notifications turned on, you might miss our next alerts. NFA

1 · Reply

NinjaXLightning Jul. 2 at 3:49 PM

$EDIT and $TREE about to pop off, $OUST taking a breather. Monster reversals are not straight up.

0 · Reply

NinjaXLightning Jul. 2 at 3:42 PM

$EDIT $10 by year end, $20 by end of 2027, $100 by 2035.

0 · Reply

alexx013 Jul. 2 at 2:29 PM

$EDIT nice

0 · Reply

RedTop1 Jul. 2 at 2:03 PM

$EDIT Cha Ching! Paying off after years of accumulations! 10K plus shrs.

0 · Reply

0x126 Jul. 1 at 8:57 PM

$EDIT almost a million bought up 5%, 100 sold 5% down. Woah

0 · Reply

0x126 Jul. 1 at 8:25 PM

$EDIT getting there today

0 · Reply

Whoami1989 Jul. 1 at 5:52 PM

$EDIT monster reverse ? this fpos hasnt gone anywhere .

1 · Reply

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Jun 17, 2026, 8:30 AM EDT - 17 days ago

Editas Medicine Transcript: AGM 2026

Jun 4, 2026, 2:00 PM EDT - 4 weeks ago

Editas Medicine Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 4:01 PM EDT - 5 weeks ago

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

2026-05-27T16:33:49.000Z - 5 weeks ago

Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI

2026-05-27T16:16:51.000Z - 5 weeks ago

TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’

2026-05-26T13:43:57.000Z - 5 weeks ago

Editas Medicine 55.6M share Secondary priced at $2.25

May 26, 2026, 9:05 AM EDT - 5 weeks ago

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

2026-05-26T10:36:17.000Z - 5 weeks ago

Editas Medicine announces common stock, warrant offering, no amount given

May 26, 2026, 6:15 AM EDT - 5 weeks ago

Editas Medicine Announces Proposed Public Offering

2026-05-26T10:14:07.000Z - 5 weeks ago

Editas Medicine presented preclinical data for EDIT-401 at EAS Congress

May 26, 2026, 6:01 AM EDT - 5 weeks ago

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

2026-05-14T10:29:14.000Z - 7 weeks ago

Editas Medicine’s EDIT-401 shows efficacy and safety in hyperlipidemia

May 14, 2026, 6:01 AM EDT - 7 weeks ago

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

2026-05-05T11:49:57.000Z - 2 months ago

Editas Medicine reports Q1 EPS (26c), consensus (24c)

May 5, 2026, 7:00 AM EDT - 2 months ago

Editas Medicine Announces First Quarter 2026 Results and Business Updates

May 5, 2026, 7:00 AM EDT - 2 months ago

Editas Medicine Earnings release: Q1 2026

May 5, 2026, 7:00 AM EDT - 2 months ago

Editas Medicine Quarterly report: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Editas Medicine Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Editas Medicine Proxy statement: Proxy filing

Apr 27, 2026, 4:31 PM EDT - 2 months ago

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Apr 21, 2026, 3:00 PM EDT - 2 months ago

Editas Medicine Slides: Corporate presentation

Apr 16, 2026, 7:00 AM EDT - 2 months ago

Editas Medicine Slides: Corporate presentation

2026-04-13T13:45:59.000Z - 2 months ago

Editas Medicine price target raised to $15 from $13 at Evercore ISI

2026-03-27T11:15:12.000Z - 3 months ago

Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents

Mar 27, 2026, 7:00 AM EDT - 3 months ago

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Mar 12, 2026, 8:30 AM EDT - 4 months ago

Editas Medicine Transcript: Barclays 28th Annual Global Healthcare Conference

2026-03-10T14:25:34.000Z - 4 months ago

Editas Medicine upgraded to Buy from Hold at JonesResearch

2026-03-09T11:05:44.000Z - 4 months ago

Editas Medicine reports Q4 EPS (6c), consensus (26c)

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Editas Medicine Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Editas Medicine Earnings release: Q4 2025

Mar 2, 2026, 10:30 AM EST - 4 months ago

Editas Medicine Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 9:00 AM EST - 4 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Jan 19, 2026, 2:20 AM EST - 5 months ago

Genflow Biosciences PLC Announces Directorate Change

Dec 2, 2025, 9:10 AM EST - 7 months ago

Editas Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-11-12T22:30:52.000Z - 8 months ago

Editas Medicine price target lowered to $3.50 from $12 at Chardan

2025-11-10T21:40:13.000Z - 8 months ago

Editas Medicine price target raised to $4.60 from $4 at Clear Street

2025-11-10T12:20:51.000Z - 8 months ago

Editas Medicine reports Q3 EPS (28c), consensus (38c)

Nov 10, 2025, 7:00 AM EST - 8 months ago

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 10, 2025, 7:00 AM EST - 8 months ago

Editas Medicine Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Editas Medicine Earnings release: Q3 2025

Nov 3, 2025, 9:00 AM EST - 8 months ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Oct 21, 2025, 8:45 AM EDT - 9 months ago

Editas Medicine Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 14, 2025, 7:00 AM EDT - 9 months ago

Editas Medicine Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Oct 9, 2025, 11:01 AM EDT - 9 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 9 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 4, 2025, 11:30 AM EDT - 10 months ago

Editas Medicine Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Editas Medicine Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Editas Medicine Transcript: Status Update

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Editas Medicine Press release: Status Update

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Editas Medicine Slides: Status Update

Sep 2, 2025, 7:00 AM EDT - 10 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 11 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 12, 2025, 4:01 PM EDT - 11 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Aug 12, 2025, 9:30 AM EDT - 11 months ago

Editas Medicine Quarterly report: Q2 2025

Aug 12, 2025, 9:30 AM EDT - 11 months ago

Editas Medicine Earnings release: Q2 2025

Jun 12, 2025, 2:01 AM EDT - 1 year ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 28, 2025, 7:00 AM EDT - 1 year ago

Editas Medicine Slides: Corporate Presentation

May 14, 2025, 9:31 AM EDT - 1 year ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 1 year ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 8:15 PM EDT - 1 year ago

Editas Medicine Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 7:01 AM EDT - 1 year ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 1 year ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 12, 2025, 9:30 AM EDT - 1 year ago

Editas Medicine Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Editas Medicine Earnings release: Q1 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 1 year ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Editas Medicine Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Editas Medicine Proxy statement: Proxy Filing

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Editas Medicine Slides: Corporate Presentation

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Editas Medicine Proxy statement: Proxy Filing

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 9:00 AM EDT - 1 year ago

Editas Medicine Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Editas Medicine Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 4:05 PM EST - 1 year ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 5, 2025, 9:30 AM EST - 1 year ago

Editas Medicine Annual report: Q4 2024

Mar 5, 2025, 9:30 AM EST - 1 year ago

Editas Medicine Earnings release: Q4 2024

Mar 3, 2025, 2:30 PM EST - 1 year ago

Editas Medicine Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 15, 2025, 2:15 PM EST - 1 year ago

Editas Medicine Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 12:44 PM EST - 1 year ago

Editas Medicine Slides: Corporate Presentation

Jan 13, 2025, 9:00 AM EST - 1 year ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 5:00 PM EST - 1 year ago

Editas Medicine Transcript: Strategy Update

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 1:20 PM EST - 1 year ago

Editas Medicine Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 19, 2024, 1:50 PM EST - 1 year ago

Editas Medicine Transcript: Stifel 2024 Healthcare Conference

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Nov 4, 2024, 7:30 AM EST - 1 year ago